Sözeri Elif, Kutlutürkan Sevinç
Department of Nursing, Gazi University Faculty of Health Sciences, Ankara, Turkey.
J Breast Health. 2015 Apr 1;11(2):81-87. doi: 10.5152/tjbh.2015.2489. eCollection 2015 Apr.
This study is aimed to determine factors that affect conditions of patients receiving chemotherapy in terms of experienced taste alteration.
In this descriptive study, 184 patients receiving chemotherapy were included in the sample. Data were collected during the period of December 2013 to May 2014 using "Patient Characteristics Identification Form" and "Chemotherapy-induced Taste Alteration Scale (CiTAS)." The data were analyzed using SPSS 20 (SPSS Inc., Chicago IL, USA) statistical software in terms of number, percentage, Mann-Whitney U test, and Kruskal-Wallis H test.
The mean age of the patients was 55.5±11.8 and 57.1% of them were female. The clinical diagnosis of the patients were most frequently breast cancer (n=46), colorectal cancer (n=45), and lung cancer (n=25). Furthermore, 37.5% of the patients were in clinical stage II; 15.8% of the patients received paclitaxel+herceptin and 14.1% received gemcitabine+cisplatin chemotherapy protocols. Data demonstrated significant differences in mean scores (p<0.05) taken from "Decline in Basic Taste" and "Phantogeusia and Parageusia" subscales with patients with or without xerostomia. There were significant differences in the average scores of the subscales between those with and without a sore mouth "Discomfort" and "General taste alterations" (p<0.05).
It has been established that patients receiving chemotherapy experience substantial alteration in taste by exposure of different subscales of CiTAS. Analysis of scores collected from different subscales of CiTAS with respect to sociodemographic and pathological differences showed that patients with xerostomia and sore mouth experienced more severe taste alterations.
本研究旨在确定在经历味觉改变方面影响接受化疗患者状况的因素。
在这项描述性研究中，样本纳入了184名接受化疗的患者。2013年12月至2014年5月期间，使用“患者特征识别表”和“化疗引起的味觉改变量表（CiTAS）”收集数据。使用SPSS 20（美国伊利诺伊州芝加哥市SPSS公司）统计软件，从数量、百分比、曼-惠特尼U检验和克鲁斯卡尔-沃利斯H检验方面对数据进行分析。
患者的平均年龄为55.5±11.8岁，其中57.1%为女性。患者的临床诊断最常见的是乳腺癌（n = 46）、结直肠癌（n = 45）和肺癌（n = 25）。此外，37.5%的患者处于临床II期；15.8%的患者接受紫杉醇+赫赛汀化疗方案，14.1%的患者接受吉西他滨+顺铂化疗方案。数据显示，有或无口干症的患者在“基本味觉减退”和“幻味和异味”子量表中的平均得分存在显著差异（p<0.05）。有或无口腔疼痛的患者在“不适”和“总体味觉改变”子量表的平均得分存在显著差异（p<0.05）。
已证实接受化疗的患者通过CiTAS不同子量表的暴露会经历味觉的实质性改变。对CiTAS不同子量表收集的分数就社会人口统计学和病理差异进行分析表明，有口干症和口腔疼痛的患者经历的味觉改变更严重。
